The goal of the LymeX Diagnostics Prize is to develop diagnostics that can accurately detect active Lyme disease infections in people. The multiphase competition will nurture the development of innovative solutions toward Food and Drug Administration review. Phase 1 awarded $1 million. At the discretion of HHS and the Steven & Alexandra Cohen Foundation, and subject to availability of future funding, at least one additional phase may follow Phase 2. Future phases are expected to focus on clinical and nonclinical validation of diagnostic test(s) that detect active infection by Lyme-disease-causing bacteria, as well as readiness for regulatory submission and market entry. Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Steven & Alexandra Cohen Foundation, $9 million in additional LymeX prizes are projected to be available to proposed future phases.